Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
This article was originally published in Pharmaceutical Approvals Monthly
Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee
You may also be interested in...
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed
Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.
The Oncologic Drugs Advisory Committee will determine the legitimacy of retrospective trials used to determine predictive biomarkers during review of K-ras data for Erbitux and Vectibix.